BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32334500)

  • 1. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome.
    Mandpe P; Prabhakar B; Shende P
    Curr Drug Metab; 2020; 21(2):79-88. PubMed ID: 32334500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
    Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V
    BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

  • 7. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR; Siddiqui E
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
    Sharaf A; Hashim H
    Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
    Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
    J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
    Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S
    J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.
    Iitsuka H; van Gelderen M; Katashima M; Takusagawa S; Sawamoto T
    Clin Ther; 2015 May; 37(5):1031-44. PubMed ID: 25791612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
    Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
    Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
    Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.